|
注册号: Registration number: |
ChiCTR2500097636 |
|
最近更新日期: Date of Last Refreshed on: |
2025-02-23 19:00:01 |
|
注册时间: Date of Registration: |
2025-02-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
间歇性Theta波爆发式刺激对脑卒中患者上肢运动功能的影响 |
|
Public title: |
Effects of Intermittent Theta Burst Stimulation on Upper Limb Motor Function in Stroke Patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
间歇性Theta波爆发式刺激对脑卒中患者上肢运动功能的影响 |
|
Scientific title: |
Effects of Intermittent Theta Burst Stimulation on Upper Limb Motor Function in Stroke Patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
付艳鑫 |
研究负责人: |
武亮 |
|
Applicant: |
Yanxin Fu |
Study leader: |
Liang Wu |
|
申请注册联系人电话: Applicant telephone: |
+86 188 3437 2203 |
研究负责人电话:
Study leader's |
+86 152 1087 8101 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
fuyanxin0206@163.com |
研究负责人电子邮件: Study leader's E-mail: |
1972wuliang@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市昌平区小汤山镇温泉街390号 |
研究负责人通讯地址: |
北京市昌平区小汤山镇温泉街390号 |
|
Applicant address: |
390 Wenquan Street, Xiaotangshan, Changping District, Beijing, China |
Study leader's address: |
390 Wenquan Street, Xiaotangshan, Changping District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
天津体育学院 |
||
|
Applicant's institution: |
Tianjin University of Sport |
||
|
研究负责人所在单位: |
北京小汤山医院 |
||
|
Affiliation of the Leader: |
Beijing Xiaotangshan Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2025]伦审第(01)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京小汤山医院伦理审查委员会 |
||
|
Name of the ethic committee: |
Beijing Xiaotangshan Hospital Ethics Review Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-01-21 00:00:00 | ||
|
伦理委员会联系人: |
李佳航 |
||
|
Contact Name of the ethic committee: |
Jiahang Li |
||
|
伦理委员会联系地址: |
北京市昌平区小汤山镇银街北路390号 |
||
|
Contact Address of the ethic committee: |
390 Wenquan Street, Xiaotangshan, Changping District, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6178 9598 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京小汤山医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Xiaotangshan Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市昌平区小汤山镇温泉街390号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
390 Wenquan Street, Xiaotangshan, Changping District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
none |
||||||||||||||||||||||
|
研究疾病: |
脑卒中 |
||||||||||||||||||||||
|
Target disease: |
Stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
(1)本研究采用间歇性Theta波爆发式刺激(intermittent theta burst stimulation,iTBS)和传统5Hz高频重复经颅磁刺激(high-frequency repetitive transcranial magnetic stimulation, HF-rTMS)对伴有上肢运动功能障碍的脑卒中患者进行干预,评估两种兴奋性经颅磁刺激模式对脑卒中患者上肢运动功能的影响。(2)明确两种模式的疗效差异,治疗效果从上肢运动功能恢复的临床表现及神经电生理层面进行评估,同时监测上肢感觉指标。(3)为有效改善卒中患者上肢运动功能的干预方法提供客观的试验依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) Intermittent Theta wave burst stimulation (iTBS) and traditional 5 Hz high frequency repetitive transcranial magnetic stimulation (HF-rTMS) were used to intervene stroke patients with upper limb motor dysfunction. To evaluate the effects of two excitatory transcranial magnetic stimulation modalities on upper extremity motor function in stroke patients. (2) To clarify the difference in curative effect between the two modes, and evaluate the treatment effect from the clinical signs of upper limb motor function recovery and neuroelectrophysiology, while monitoring the sensory indicators of the upper limb. (3) To provide an objective experimental basis for effective intervention methods to improve upper limb motor function in stroke patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
①头颅内金属异物者,带有植入式脉冲刺激发生器或药物泵者,有耳蜗植入者;②有高风险出现噪音性听力丧失的人(包括接受耳毒性药物治疗和接触溶剂的人)、有听觉过敏症状的患者;③妊娠期患者;④严重或近期心脏病者;⑤既往有癫痫史,有严重的心、肺、肝、肾等重要脏器功能衰竭者及有颅内高压症状者;⑥严重的认知、交流障碍、情绪障碍、烦躁等不能配合者;⑦参与本研究前3个月之内接受过iTBS或HF-rTMS治疗者;⑧有颅骨或手部存在缺陷等;⑨研究者认为不适合参与试验。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1 metallic foreign body in the head, with implantable pulse stimulation generator or drug pump, cochlear implant; 2 people at high risk of noise-induced hearing loss (including those treated with ototoxic drugs and those exposed to solvents), people with hyperacusis symptoms; 3 Pregnant patients; 4 severe or recent heart disease; 5 history of epilepsy, severe heart, lung, liver, kidney and other important organ failure, and intracranial hypertension; 6 severe cognitive, communication disorders, emotional disorders, irritability and other inability to cooperate; 7 those who received iTBS or HF-rTMS within 3 months before the study; 8 Skull or hand defects; 9 The investigator considered it inappropriate to participate in the trial. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-12 00:00:00至 To 2026-01-12 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-02-24 00:00:00 至 To 2026-01-12 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
实验不相干者;随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Experiment irrelevant;Random number table |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据管理采用纸质+电子管理流程,制定电子版CRF表,每位受试者一份,并打印出来,存放于指定位置此表主要内容包括受试者基本信息、临床相关资料、知情同意书、随访记录、副作用量表等。测试的相关数据则录入指定电脑,采用电子化管理流程,进行严格的数据管理与质量控制。 当患者剔除、脱落后,研究者应尽可能与患者联系,完成所能完成的评估项目,并填写试验结束表,详细记录试验治疗记录。对因不良反应而脱落者,经随访最后判断与试验有关者,必须记录在CRF表并通知申办者。对任何脱落病例,研究者必须在CRF表中填写脱落的原因,一般情况下有6种:即不良事件、缺乏疗效、违背试验方案(包括依从性差者)、失访(包括患者自行退出)、被申办者中止和其他。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Each subject had one copy of the electronic CRF form, which was printed out and stored in the designated place. The main contents of the form included the basic information of the subjects, clinical related data, informed consent, follow-up records, side effects scale, etc. The relevant data of the test is entered into the designated computer, and the electronic management process is adopted to carry out strict data management and quality control. When a patient was excluded or dropped out, the investigator should contact the patient as much as possible to complete the evaluation items that could be completed, fill in the end of the trial form, and record the trial treatment record in detail. Dropouts due to adverse events should be recorded on the CRF form and notified to the sponsor. For any dropouts, investigators were required to fill in the CRF form the reasons for dropouts, which generally included six reasons: adverse events, lack of efficacy, protocol violations (including nonadherence), loss to follow-up (including withdrawal by the patient), discontinuation by the sponsor, and others. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |